Who we are

celebrating 20 years Our manufacturing capabilities

Primary sites

 
 
 
PORT ELIZABETH, SOUTH AFRICA   BAD OLDESLOE, GERMANY   NOTRE DAME DE BONDEVILLE, FRANCE

UNIT 1 FACILITY

Capability: High-volume solids manufacturing and packing for domestic and export markets.

Maximum output:
6 billion tablets.

 

UNIT 2 FACILITY

Capability: Small to medium-volume solids manufacturing for domestic and export markets.

Maximum output:
4 billion tablets.

 

UNIT 3 FACILITY

Capability: End state packing for domestic market.

Maximum output:
140 million packed units of tablets and capsules.

 

UNIT 4 FACILITY

Capability: Hormonal and high-potency solids manufacturing and packaging for the domestic and export markets.

Maximum output:
3,2 billion tablets (hormonal);
395 million tablets (potency).

STERILE FACILITY SVP 1:

MULTI-PRODUCT SUITES A AND B

Capability: Eye drops, ampoules, liquid and lyophilised vials for domestic and export markets.

Maximum output:
Suite A: 42 million units of eye drops;
2,9 million units of liquid vials;
Suite B: 11,75 million units of ampoules;
23,5 million units of liquid vials.

 

STERILE FACILITY SVP 2:

HIGH-POTENCY SUITE

Capability: Prefilled syringes for domestic and export markets.

Maximum output:
Phase 1: 110 million prefilled syringes.

       
 

MULTI-DOSE FORM SUITE

Capability: Solid dose forms, oral and topical liquids, semi-solids and blow-fill seal, manufacturing and packing for domestic and export markets.

Maximum output:
3,3 billion tablets; 6 240 tonnes of liquids; 1 404 tonnes of topical liquids; 351 tonnes of semi-solids, 60 million units for blow-fill seals.

 

STERILE PREFILLED SYRINGE MANUFACTURING SITE

Capability: Aseptic prefilled and terminally sterilised syringe manufacturing and packing for domestic and export markets.

Maximum output:
85 million syringes (Etna line);
130 million syringes (Stromboli line);
180 million syringes (Vesuve line).

17
sites
globally

Details of the additional 10 regional sites, accreditation, abbreviations and acronyms are available online

25
manufacturing
facilities
1997 to 2004 4 total sites 2005 to 2009 9 total sites 2010 to 2017 17 total sites
 
 
 

API facilities

SIOUX CITY, USA   CAPE TOWN, SOUTH AFRICA   NOTRE DAME DE BONDEVILLE, FRANCE

API FACILITY

Capability: Specialist biochemical API – heparin intermediates.

Maximum output:
Biologicals – capacity is measured on demand – dependent on product mix.

 

FCC API FACILITY

Capability: Specialised API and high potency manufacturing for domestic and export markets.

Maximum output:
46 000kg.

 

NADROPARIN

Capability: Specialised biochemical API – conversion of heparin to nadroparin.

Maximum output:
200 batches of nadroparin.

CERTOPARIN

Capability: Specialised biochemical API – conversion of heparin to certoparin.

Maximum output:
45 batches of certoparin.

FONDAPARINUX FACILITY

Capability: Specialised chemical API – purification by chromatography of fondaparinux.

Maximum output:
34 batches of fondaparinux sodium.

 
OSS, THE NETHERLANDS

DE GEER SITE

Capability: Specialised hormonal
and chemical APIs.

Maximum output:
150KvH.

MOLENEIND SITE

Capability: Specialised biochemical,
hormonal and chemical APIs.

Maximum output:
Dependent on product mix.

BOXTEL SITE

Capability: Specialised biochemical
API – gonadotrophin intermediates.

Maximum output:
Measured on demand.